Target- |
MechanismImmunostimulants |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc.US |
First Approval Date27 Nov 2009 |
A Phase 3, Randomized, Observer-blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine in Comparison with a Licensed Quadrivalent Influenza Vaccine, in Adults 50 to 64 Years of Age - Phase 3 Immunogenicity Study of aQIV in Adults 50 to 64 Years of Age
100 Clinical Results associated with Seqirus UK Ltd.
0 Patents (Medical) associated with Seqirus UK Ltd.
100 Deals associated with Seqirus UK Ltd.
100 Translational Medicine associated with Seqirus UK Ltd.